Consortium invest £8m in KalVista

The investors were attracted to the deal because they believe KalVista has the scientific, clinical and development expertise to capitalise on a new approach to treating diabetic macular edema. Funding will support further development of the company.

Company
KalVista Pharmaceuticals is a newly established ophthalmology company with a focus on diabetic macular edema (DME). DME is a leading cause of adult vision loss in developed countries and KalVista's new approach to treatment involves novel plasma kallikrein inhibitors.

The company is based in Southampton.

People
Graham Boulnois and Martin Edwards worked on the deal for SV Life Sciences and Novo A/S respectively. They will represent their investors on the company's board of directors, Boulnois as chairman and Edwards as non-executive director.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• UK / Ireland
• Early-stage
• Healthcare
• United Kingdom